Benmelstobart+anlotinib: an emerging therapeutic option in the targeted-immunotherapy era

In recent years, with the gradual deepening of research, basic and clinical studies on targeted-immunotherapy combination regimens have flourished and yielded exciting results. The novel programmed cell death ligand 1 (PD-L1) inhibitor benmelstobart in combination with the targeted agent anlotinib demonstrates synergistic antitumor effects, achieving a synergy therapeutic outcome. This article focuses on the mechanisms underlying the combined action of "benmelstobart+anlotinib", summarizes the currently approved indications and clinical research progress, and aims to provide alternative therapeutic options for patients with malignant tumors as well as new insights for the development and selection of future combination treatment strategies.